Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years

Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years

Item
http://www.wikidata.org/entity/Q37115262
Vaccination of adolescents with chronic medical conditions: Special considerations and strategies for enhancing uptakeInfections and Systemic Lupus Erythematosus: Binding or Sparring Partners?HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should knowSafety of human papillomavirus vaccines: a reviewEULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndromeRisk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort studyVaccinations in paediatric rheumatology: an update on current developments.A literature review on the patients with autoimmune diseases following vaccination against infections.Vaccine-preventable infections in Systemic Lupus Erythematosus.Vaccination of patients with autoimmune inflammatory rheumatic diseases.The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases.Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome) - An update.Advances in our understanding of immunization and vaccines for patients with systemic lupus erythematosus.Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis.
P2860

Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years

Item
http://www.wikidata.org/entity/Q37115262
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety and immunogenicity of t ...... s patients aged 12 to 26 years
@en
Safety and immunogenicity of t ...... patients aged 12 to 26 years.
@nl
type
label
Safety and immunogenicity of t ...... s patients aged 12 to 26 years
@en
Safety and immunogenicity of t ...... patients aged 12 to 26 years.
@nl
prefLabel
Safety and immunogenicity of t ...... s patients aged 12 to 26 years
@en
Safety and immunogenicity of t ...... patients aged 12 to 26 years.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P478
P577
P5875
P6179
P698
P932
P356
P1433
P1476
Safety and immunogenicity of t ...... s patients aged 12 to 26 years
@en
P2093
P2860
P2888
P304
P31
P356
P478
P577
P5875
P6179
P698
P932